Clinical and Objective Psychiatric Analyses in Severe Depression. (CALYPSO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06095310 |
Recruitment Status :
Not yet recruiting
First Posted : October 23, 2023
Last Update Posted : October 23, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Participation in the CALYPSO project will be offered to all patients with severe depression hospitalized in the adult psychiatry department of Lille CHU.
An initial visit will provide a standardized clinical assessment with: a medical history and history of the disease, a standardized structured Hamilton scale interview (scale with a score from 0 to 21; the higher the score, the more severe the depression) to assess the severity of depression, and a search for the different features of severe depression (melancholic, psychotic, anxious, catatonic, seasonal) using DSM-5 criteria (list of criteria to be validated to determine the type of clinical features). When assessing the severity of depression using the Hamilton scale interview, the patient will be seated in an armchair 2 to 3 meters from a camera on a tripod, positioned behind the clinician and enabling the entire interview to be recorded and, in particular, several observable and measurable psychiatric signs and symptoms, known as objective markers. From the video will be extracted face landmark and pose parameter using state-of-the-art open source software (Mediapipe) to analyze patients' emotional facial expressions and spatial movements. Moreover, a microphone will be used to capture the audio synchronously with the video. Speech will be automatically transcoded using state-of-the-art Automatic Speech Recognition system (DeepSpeech) to enable analysis of voice-related parameters (voice timbre, prosody, sound intensity). A recording of physical activity (3-axis accelerometer sensor; 32 Hz) and emotional reactivity (heart rate in beats per minute 1Hz; electrodermal activity 4 Hz; skin temperature in degrees 4 Hz; Empatica© bracelet) and brain activity (cerebral blood flow change index 10Hz; pulse rate in bpm 10Hz; 3-axis acceleration and angular velocity of the head 10Hz via functional Near-Infrared Spectroscopy (fNIRS) using a HOT-2000 wearable headset) will also be offered to the patient to complete the assessment. The Hamilton scale interview and recording of objective markers will be carried out weekly during the patient's hospitalization in an examination room specifically equipped for the project, on the second floor of the Fontan Hospital, in the psychiatry department of the Lille University hospital.
Longitudinal follow-up will be carried out with assessments at 3, 6 and 12 months after hospital discharge, including the Hamilton scale interview and recording of objective markers (i.e., emotional facial expressions, spatial movements, voice timbre, prosody, sound intensity, physical activity, heart rate, electrodermal activity, skin temperature).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Depression | Behavioral: New computer vision methods | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Evaluation of New Computer Vision Methods to Characterize Depression Severity in Patients Hospitalized for Severe Depression. |
Estimated Study Start Date : | November 2023 |
Estimated Primary Completion Date : | November 2027 |
Estimated Study Completion Date : | November 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Homogeneous groups |
Behavioral: New computer vision methods
Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS) |
- Severity of depression and clinical characteristics. [ Time Frame: The primary outcome is measured at the initial visit, then at assessments at 3, 6 and 12 months after hospital discharge. ]The severity of depression will be assessed with the interview on the Hamilton scale (a scale with a score from 0 to 21; the higher the score, the more severe the depression), and clinical features will be determined according to DSM-5 criteria (list of criteria to be validated to determine the type of clinical features).
- Objective markers of remission of depressive episode [ Time Frame: The secondary outcome is measured at the initial visit, then at assessments at 3, 6 and 12 months after hospital discharge. ]The interviews will be filmed and recorded in order to collect objective markers of depression (i.e., emotional facial expressions, spatial movements, voice timbre, prosody, sound intensity, physical activity, heart rate, electrodermal activity, skin temperature).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female, over 18 years of age
- with severe depression as defined by DSM-5 criteria hospitalized in the adult psychiatry department of Lille University Hospital.
- Socially insured
- Patient willing to comply with all study procedures and duration.
Exclusion Criteria:
- Refusal to participate after receiving clear and fair information about the study
- Pregnant or breast-feeding women
- Person deprived of liberty or under guardianship or curatorship
Responsible Party: | University Hospital, Lille |
ClinicalTrials.gov Identifier: | NCT06095310 |
Other Study ID Numbers: |
2021-0366 2022-A01160-43 ( Other Identifier: ID-RCB number, ANSM ) |
First Posted: | October 23, 2023 Key Record Dates |
Last Update Posted: | October 23, 2023 |
Last Verified: | January 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Psychiatry prediction depression objective psychiatry personalized treatments |
evolution and prognosis computer science artificial intelligence innovation |
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders |